SK9132001A3 - Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors - Google Patents

Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors Download PDF

Info

Publication number: SK9132001A3
Authority: SK; Slovakia
Prior art keywords: receptor; receptors; treatment; diseases; pharmaceutically acceptable
Prior art date: 1998-12-23

Application number

SK913-2001A

Other languages

English (en)

Slovak (sk)

Inventor

Gillian Rosemary Bullock

Gasparo Marc De

Sabina Maria Ganter

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-12-23

Filing date

1999-12-22

Publication date

2002-01-07

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26152118&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK9132001(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-12-23 Priority claimed from EP98811258A external-priority patent/EP1013273A1/fr

1999-12-22 Application filed by Novartis Ag filed Critical Novartis Ag

2002-01-07 Publication of SK9132001A3 publication Critical patent/SK9132001A3/sk

Links

208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 24
201000010099 disease Diseases 0.000 title claims abstract description 16
229940075993 receptor modulator Drugs 0.000 title claims abstract description 10
239000002333 angiotensin II receptor antagonist Substances 0.000 title claims abstract description 8
239000000400 angiotensin II type 1 receptor blocker Substances 0.000 title claims abstract description 6
150000003839 salts Chemical class 0.000 claims abstract description 26
238000011282 treatment Methods 0.000 claims abstract description 24
210000000981 epithelium Anatomy 0.000 claims description 21
239000002464 receptor antagonist Substances 0.000 claims description 13
229940044551 receptor antagonist Drugs 0.000 claims description 13
210000002919 epithelial cell Anatomy 0.000 claims description 11
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 10
239000003814 drug Substances 0.000 claims description 10
238000004519 manufacturing process Methods 0.000 claims description 10
206010006451 bronchitis Diseases 0.000 claims description 8
208000035475 disorder Diseases 0.000 claims description 8
206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 6
201000009030 Carcinoma Diseases 0.000 claims description 6
208000019693 Lung disease Diseases 0.000 claims description 6
208000020816 lung neoplasm Diseases 0.000 claims description 6
239000008194 pharmaceutical composition Substances 0.000 claims description 6
206010006458 Bronchitis chronic Diseases 0.000 claims description 5
206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 5
208000007451 chronic bronchitis Diseases 0.000 claims description 5
201000005202 lung cancer Diseases 0.000 claims description 5
230000000414 obstructive effect Effects 0.000 claims description 5
208000011580 syndromic disease Diseases 0.000 claims description 5
206010016654 Fibrosis Diseases 0.000 claims description 4
206010061218 Inflammation Diseases 0.000 claims description 4
230000004761 fibrosis Effects 0.000 claims description 4
230000004054 inflammatory process Effects 0.000 claims description 4
210000002570 interstitial cell Anatomy 0.000 claims description 4
230000002062 proliferating effect Effects 0.000 claims description 4
102000008186 Collagen Human genes 0.000 claims description 3
108010035532 Collagen Proteins 0.000 claims description 3
206010014561 Emphysema Diseases 0.000 claims description 3
208000003241 Fat Embolism Diseases 0.000 claims description 3
206010033650 Pancreatitis haemorrhagic Diseases 0.000 claims description 3
206010035664 Pneumonia Diseases 0.000 claims description 3
238000009825 accumulation Methods 0.000 claims description 3
208000006673 asthma Diseases 0.000 claims description 3
230000002612 cardiopulmonary effect Effects 0.000 claims description 3
230000004663 cell proliferation Effects 0.000 claims description 3
210000000038 chest Anatomy 0.000 claims description 3
229920001436 collagen Polymers 0.000 claims description 3
208000014674 injury Diseases 0.000 claims description 3
230000035939 shock Effects 0.000 claims description 3
230000001988 toxicity Effects 0.000 claims description 3
231100000419 toxicity Toxicity 0.000 claims description 3
201000003883 Cystic fibrosis Diseases 0.000 claims description 2
208000004756 Respiratory Insufficiency Diseases 0.000 claims description 2
230000006378 damage Effects 0.000 claims description 2
208000030776 invasive breast carcinoma Diseases 0.000 claims description 2
231100000516 lung damage Toxicity 0.000 claims description 2
201000004193 respiratory failure Diseases 0.000 claims description 2
208000027771 Obstructive airways disease Diseases 0.000 claims 1
208000027418 Wounds and injury Diseases 0.000 claims 1
230000001684 chronic effect Effects 0.000 claims 1
210000002784 stomach Anatomy 0.000 claims 1
239000000825 pharmaceutical preparation Substances 0.000 abstract description 4
108020003175 receptors Proteins 0.000 description 87
102000005962 receptors Human genes 0.000 description 87
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 42
150000001875 compounds Chemical class 0.000 description 40
210000004072 lung Anatomy 0.000 description 32
239000004072 C09CA03 - Valsartan Substances 0.000 description 28
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 28
229960004699 valsartan Drugs 0.000 description 27
ACWBQPMHZXGDFX-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 ACWBQPMHZXGDFX-QFIPXVFZSA-N 0.000 description 27
238000009826 distribution Methods 0.000 description 26
239000003826 tablet Substances 0.000 description 23
210000001519 tissue Anatomy 0.000 description 23
238000000034 method Methods 0.000 description 21
239000007787 solid Substances 0.000 description 21
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 19
210000004027 cell Anatomy 0.000 description 18
239000000203 mixture Substances 0.000 description 17
229920000168 Microcrystalline cellulose Polymers 0.000 description 16
239000004480 active ingredient Substances 0.000 description 16
239000008108 microcrystalline cellulose Substances 0.000 description 16
229940016286 microcrystalline cellulose Drugs 0.000 description 16
235000019813 microcrystalline cellulose Nutrition 0.000 description 16
239000000377 silicon dioxide Substances 0.000 description 16
229960000913 crospovidone Drugs 0.000 description 15
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 15
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 15
235000019359 magnesium stearate Nutrition 0.000 description 14
239000002775 capsule Substances 0.000 description 13
208000006402 Ductal Carcinoma Diseases 0.000 description 12
239000000523 sample Substances 0.000 description 12
239000006186 oral dosage form Substances 0.000 description 11
238000010186 staining Methods 0.000 description 11
206010028980 Neoplasm Diseases 0.000 description 10
210000004907 gland Anatomy 0.000 description 10
239000008187 granular material Substances 0.000 description 10
238000007901 in situ hybridization Methods 0.000 description 10
210000000329 smooth muscle myocyte Anatomy 0.000 description 10
-1 1-carboxy-2-methylprop-1-yl Chemical group 0.000 description 9
210000002950 fibroblast Anatomy 0.000 description 9
235000010213 iron oxides and hydroxides Nutrition 0.000 description 9
239000004407 iron oxides and hydroxides Substances 0.000 description 9
230000004807 localization Effects 0.000 description 9
206010020772 Hypertension Diseases 0.000 description 8
239000007941 film coated tablet Substances 0.000 description 8
239000004615 ingredient Substances 0.000 description 8
239000000546 pharmaceutical excipient Substances 0.000 description 8
238000012545 processing Methods 0.000 description 8
CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 7
102000005862 Angiotensin II Human genes 0.000 description 7
101800000733 Angiotensin-2 Proteins 0.000 description 7
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 7
239000002253 acid Substances 0.000 description 7
229950006323 angiotensin ii Drugs 0.000 description 7
229910002016 Aerosil® 200 Inorganic materials 0.000 description 6
108050000824 Angiotensin II receptor Proteins 0.000 description 6
102000008873 Angiotensin II receptor Human genes 0.000 description 6
208000026310 Breast neoplasm Diseases 0.000 description 6
150000007513 acids Chemical class 0.000 description 6
239000013543 active substance Substances 0.000 description 6
201000011510 cancer Diseases 0.000 description 6
238000000576 coating method Methods 0.000 description 6
238000007906 compression Methods 0.000 description 6
230000006835 compression Effects 0.000 description 6
238000001514 detection method Methods 0.000 description 6
229940079593 drug Drugs 0.000 description 6
238000009472 formulation Methods 0.000 description 6
210000002540 macrophage Anatomy 0.000 description 6
238000002156 mixing Methods 0.000 description 6
238000003752 polymerase chain reaction Methods 0.000 description 6
206010006187 Breast cancer Diseases 0.000 description 5
208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 5
210000000481 breast Anatomy 0.000 description 5
239000011248 coating agent Substances 0.000 description 5
239000000306 component Substances 0.000 description 5
208000028715 ductal breast carcinoma in situ Diseases 0.000 description 5
230000000694 effects Effects 0.000 description 5
108020004999 messenger RNA Proteins 0.000 description 5
229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
238000003825 pressing Methods 0.000 description 5
239000007909 solid dosage form Substances 0.000 description 5
238000012360 testing method Methods 0.000 description 5
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
206010073094 Intraductal proliferative breast lesion Diseases 0.000 description 4
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 4
210000004404 adrenal cortex Anatomy 0.000 description 4
210000004100 adrenal gland Anatomy 0.000 description 4
208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 4
210000004204 blood vessel Anatomy 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
239000008119 colloidal silica Substances 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
201000007273 ductal carcinoma in situ Diseases 0.000 description 4
238000005469 granulation Methods 0.000 description 4
230000003179 granulation Effects 0.000 description 4
238000010191 image analysis Methods 0.000 description 4
238000011065 in-situ storage Methods 0.000 description 4
239000000463 material Substances 0.000 description 4
238000003801 milling Methods 0.000 description 4
239000013642 negative control Substances 0.000 description 4
239000012188 paraffin wax Substances 0.000 description 4
239000002245 particle Substances 0.000 description 4
230000007170 pathology Effects 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
208000023504 respiratory system disease Diseases 0.000 description 4
239000004408 titanium dioxide Substances 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
229920003084 Avicel® PH-102 Polymers 0.000 description 3
108020004414 DNA Proteins 0.000 description 3
238000012408 PCR amplification Methods 0.000 description 3
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
230000001919 adrenal effect Effects 0.000 description 3
230000003510 anti-fibrotic effect Effects 0.000 description 3
230000001028 anti-proliverative effect Effects 0.000 description 3
239000002585 base Substances 0.000 description 3
210000000424 bronchial epithelial cell Anatomy 0.000 description 3
238000004090 dissolution Methods 0.000 description 3
210000002889 endothelial cell Anatomy 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
UCNNJGDEJXIUCC-UHFFFAOYSA-L hydroxy(oxo)iron;iron Chemical compound [Fe].O[Fe]=O.O[Fe]=O UCNNJGDEJXIUCC-UHFFFAOYSA-L 0.000 description 3
238000007689 inspection Methods 0.000 description 3
YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 3
239000000314 lubricant Substances 0.000 description 3
239000011777 magnesium Substances 0.000 description 3
230000001575 pathological effect Effects 0.000 description 3
229940069328 povidone Drugs 0.000 description 3
235000018102 proteins Nutrition 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
239000008213 purified water Substances 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
235000019333 sodium laurylsulphate Nutrition 0.000 description 3
239000000126 substance Substances 0.000 description 3
UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
101150059573 AGTR1 gene Proteins 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
241000283707 Capra Species 0.000 description 2
208000009458 Carcinoma in Situ Diseases 0.000 description 2
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 2
CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
241001430696 Protis Species 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 2
210000001552 airway epithelial cell Anatomy 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
238000010171 animal model Methods 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
229940098773 bovine serum albumin Drugs 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
210000004081 cilia Anatomy 0.000 description 2
239000007891 compressed tablet Substances 0.000 description 2
239000008358 core component Substances 0.000 description 2
230000007423 decrease Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
239000000975 dye Substances 0.000 description 2
OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 2
239000012530 fluid Substances 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
229910052736 halogen Inorganic materials 0.000 description 2
150000002367 halogens Chemical class 0.000 description 2
206010020718 hyperplasia Diseases 0.000 description 2
238000003365 immunocytochemistry Methods 0.000 description 2
201000004933 in situ carcinoma Diseases 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
201000010985 invasive ductal carcinoma Diseases 0.000 description 2
206010073096 invasive lobular breast carcinoma Diseases 0.000 description 2
239000003446 ligand Substances 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
210000003097 mucus Anatomy 0.000 description 2
230000002018 overexpression Effects 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
229940124531 pharmaceutical excipient Drugs 0.000 description 2
230000002685 pulmonary effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
230000000391 smoking effect Effects 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
230000008733 trauma Effects 0.000 description 2
230000003827 upregulation Effects 0.000 description 2
210000003556 vascular endothelial cell Anatomy 0.000 description 2
229920000936 Agarose Polymers 0.000 description 1
208000000884 Airway Obstruction Diseases 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
229940123413 Angiotensin II antagonist Drugs 0.000 description 1
101800000734 Angiotensin-1 Proteins 0.000 description 1
102400000344 Angiotensin-1 Human genes 0.000 description 1
102000004881 Angiotensinogen Human genes 0.000 description 1
108090001067 Angiotensinogen Proteins 0.000 description 1
CKLJMWTZIZZHCS-UHFFFAOYSA-N Aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
239000002083 C09CA01 - Losartan Substances 0.000 description 1
239000002080 C09CA02 - Eprosartan Substances 0.000 description 1
239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
239000002053 C09CA06 - Candesartan Substances 0.000 description 1
239000005537 C09CA07 - Telmisartan Substances 0.000 description 1
YOSHYTLCDANDAN-UHFFFAOYSA-N CCCCC(N1Cc(cc2)ccc2-c(cccc2)c2-c2nnn[nH]2)=NC2(CCCC2)C1=O Chemical compound CCCCC(N1Cc(cc2)ccc2-c(cccc2)c2-c2nnn[nH]2)=NC2(CCCC2)C1=O YOSHYTLCDANDAN-UHFFFAOYSA-N 0.000 description 1
206010007559 Cardiac failure congestive Diseases 0.000 description 1
VWWMGPCUZVOLLK-UHFFFAOYSA-N Cc1c2nc(C3CC3)[n](Cc(cc3)ccc3-c3ccccc3C(O)=O)c2ncc1 Chemical compound Cc1c2nc(C3CC3)[n](Cc(cc3)ccc3-c3ccccc3C(O)=O)c2ncc1 VWWMGPCUZVOLLK-UHFFFAOYSA-N 0.000 description 1
241000223782 Ciliophora Species 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
241001440269 Cutina Species 0.000 description 1
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
208000000265 Lobular Carcinoma Diseases 0.000 description 1
208000004852 Lung Injury Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
108090000783 Renin Proteins 0.000 description 1
239000005478 Saprisartan Substances 0.000 description 1
DUEWVPTZCSAMNB-UHFFFAOYSA-N Saprisartan Chemical compound NC(=O)C=1N(CC=2C=C3C(Br)=C(OC3=CC=2)C=2C(=CC=CC=2)NS(=O)(=O)C(F)(F)F)C(CC)=NC=1C1CC1 DUEWVPTZCSAMNB-UHFFFAOYSA-N 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
108010006785 Taq Polymerase Proteins 0.000 description 1
206010069363 Traumatic lung injury Diseases 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102100040372 Type-2 angiotensin II receptor Human genes 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
208000037919 acquired disease Diseases 0.000 description 1
239000000654 additive Substances 0.000 description 1
238000009098 adjuvant therapy Methods 0.000 description 1
210000001943 adrenal medulla Anatomy 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
150000001447 alkali salts Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
229940127088 antihypertensive drug Drugs 0.000 description 1
239000002787 antisense oligonuctleotide Substances 0.000 description 1
230000001640 apoptogenic effect Effects 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000008512 biological response Effects 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
201000003714 breast lobular carcinoma Diseases 0.000 description 1
210000000621 bronchi Anatomy 0.000 description 1
239000001049 brown dye Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
229960000932 candesartan Drugs 0.000 description 1
SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
235000021466 carotenoid Nutrition 0.000 description 1
150000001747 carotenoids Chemical class 0.000 description 1
210000003321 cartilage cell Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000030570 cellular localization Effects 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229930002875 chlorophyll Natural products 0.000 description 1
235000019804 chlorophyll Nutrition 0.000 description 1
ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
210000001612 chondrocyte Anatomy 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical class C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
239000013599 cloning vector Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000004040 coloring Methods 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
238000004590 computer program Methods 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
239000013078 crystal Substances 0.000 description 1
230000002380 cytological effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
150000001991 dicarboxylic acids Chemical class 0.000 description 1
125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
238000001035 drying Methods 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
229960004563 eprosartan Drugs 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
230000003176 fibrotic effect Effects 0.000 description 1
238000011049 filling Methods 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
238000000227 grinding Methods 0.000 description 1
208000016356 hereditary diffuse gastric adenocarcinoma Diseases 0.000 description 1
238000001794 hormone therapy Methods 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
230000002055 immunohistochemical effect Effects 0.000 description 1
238000003364 immunohistochemistry Methods 0.000 description 1
239000000367 immunologic factor Substances 0.000 description 1
238000010874 in vitro model Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
229910052738 indium Inorganic materials 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
229960002198 irbesartan Drugs 0.000 description 1
YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
235000013980 iron oxide Nutrition 0.000 description 1
UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
229960004773 losartan Drugs 0.000 description 1
KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
231100000515 lung injury Toxicity 0.000 description 1
229960003511 macrogol Drugs 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
238000009607 mammography Methods 0.000 description 1
239000003550 marker Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
208000030163 medullary breast carcinoma Diseases 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
239000011707 mineral Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
125000000896 monocarboxylic acid group Chemical group 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
ZUHZZVMEUAUWHY-UHFFFAOYSA-N n,n-dimethylpropan-1-amine Chemical class CCCN(C)C ZUHZZVMEUAUWHY-UHFFFAOYSA-N 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
229940126701 oral medication Drugs 0.000 description 1
239000008184 oral solid dosage form Substances 0.000 description 1
229920006280 packaging film Polymers 0.000 description 1
239000012785 packaging film Substances 0.000 description 1
238000009116 palliative therapy Methods 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
102000013415 peroxidase activity proteins Human genes 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
208000028591 pheochromocytoma Diseases 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
210000004224 pleura Anatomy 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000011164 primary particle Substances 0.000 description 1
230000000861 pro-apoptotic effect Effects 0.000 description 1
208000014731 pulmonary artery disease Diseases 0.000 description 1
238000000275 quality assurance Methods 0.000 description 1
238000011002 quantification Methods 0.000 description 1
238000011158 quantitative evaluation Methods 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000029865 regulation of blood pressure Effects 0.000 description 1
230000036454 renin-angiotensin system Effects 0.000 description 1
238000002271 resection Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000009666 routine test Methods 0.000 description 1
229950006241 saprisartan Drugs 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000028327 secretion Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
239000004208 shellac Substances 0.000 description 1
238000007873 sieving Methods 0.000 description 1
229910000077 silane Inorganic materials 0.000 description 1
210000002356 skeleton Anatomy 0.000 description 1
238000009491 slugging Methods 0.000 description 1
239000012439 solid excipient Substances 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
238000005507 spraying Methods 0.000 description 1
210000004085 squamous epithelial cell Anatomy 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
150000003460 sulfonic acids Chemical class 0.000 description 1
239000000725 suspension Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
229960005187 telmisartan Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
238000004448 titration Methods 0.000 description 1
210000003437 trachea Anatomy 0.000 description 1
125000005270 trialkylamine group Chemical group 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
102000003390 tumor necrosis factor Human genes 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
230000002792 vascular Effects 0.000 description 1
239000005526 vasoconstrictor agent Substances 0.000 description 1
238000009423 ventilation Methods 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

SK913-2001A 1998-12-23 1999-12-22 Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors SK9132001A3 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP98811257		1998-12-23
EP98811258A EP1013273A1 (fr)	1998-12-23	1998-12-23	Utilisation des antagonistes du recepteur AT-1 ou des modulateurs du recepteur AT-2 pour le traitement de maladies asocciées à une augmentation de recepteurs AT-1 ou AT-2
PCT/EP1999/010330 WO2000038676A1 (fr)	1998-12-23	1999-12-22	Utilisation d'un antagoniste du recepteur d'at-1 ou d'un modulateur du recepteur d'at-2 pour traiter des affections associees a une augmentation des recepteurs d'at-1 ou d'at-2

Publications (1)

Publication Number	Publication Date
SK9132001A3 true SK9132001A3 (en)	2002-01-07

Family

ID=26152118

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK913-2001A SK9132001A3 (en)	1998-12-23	1999-12-22	Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors

Country Status (26)

Country	Link
EP (3)	EP1588706B1 (fr)
JP (2)	JP2002533390A (fr)
KR (1)	KR100646716B1 (fr)
CN (2)	CN1304000C (fr)
AT (2)	ATE524176T1 (fr)
AU (4)	AU3043000A (fr)
BR (1)	BR9916576A (fr)
CA (2)	CA2622805C (fr)
CY (2)	CY1106581T1 (fr)
CZ (2)	CZ297795B6 (fr)
DE (1)	DE69935249T2 (fr)
DK (2)	DK1140071T3 (fr)
ES (2)	ES2281978T3 (fr)
HK (1)	HK1038888B (fr)
HU (1)	HUP0104780A3 (fr)
ID (1)	ID29856A (fr)
IL (5)	IL143233A0 (fr)
NO (2)	NO328775B1 (fr)
NZ (3)	NZ587909A (fr)
PL (1)	PL199100B1 (fr)
PT (2)	PT1588706E (fr)
RU (3)	RU2271809C2 (fr)
SI (2)	SI1140071T1 (fr)
SK (1)	SK9132001A3 (fr)
TR (7)	TR200200764T2 (fr)
WO (1)	WO2000038676A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100525341B1 (ko) *	2000-06-22	2005-11-02	노파르티스 아게	고형 발사르탄 약제학적 조성물
JP4972847B2 (ja) *	2000-10-11	2012-07-11	住友化学株式会社	コラーゲン蓄積抑制剤
JPWO2002083127A1 (ja) *	2001-04-09	2004-09-30	宮田　敏男	蛋白修飾物生成抑制組成物
DE60222409T2 (de)	2001-05-31	2008-09-25	Vicore Pharma Ab	Trizyklische verbindungen, nützlich als angiotensin ii agonisten
EP1444988A4 (fr) *	2001-11-13	2007-04-25	Takeda Pharmaceutical	Agents anticancer
EG24716A (en)	2002-05-17	2010-06-07	Novartis Ag	Combination of organic compounds
WO2005041941A2 (fr) *	2003-11-03	2005-05-12	Zentiva, A.S.	Preparation contenant du valsartan
EA015108B1 (ru)	2004-12-24	2011-06-30	КРКА, д.д., НОВО МЕСТО	Способ получения твердой фармацевтической композиции, содержащей валсартан
PL1830869T3 (pl) *	2004-12-24	2013-11-29	Novartis Ag	Sposób leczenia lub profilaktyki
WO2006136916A2 (fr) *	2005-06-20	2006-12-28	Glenmark Pharmaceuticals Limited	Particules micronisees sensiblement pures de telmisartan et compositions pharmaceutiques renfermant celles-ci
GT200600371A (es)	2005-08-17	2007-03-21		Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
ES2246742B1 (es) *	2005-09-06	2007-02-01	Prous Institute For Biomedical Research S.A.	Uso de un derivado de imidazol.
US8080534B2 (en)	2005-10-14	2011-12-20	Phigenix, Inc	Targeting PAX2 for the treatment of breast cancer
CA2681708A1 (fr) *	2007-03-29	2008-10-09	Alembic Limited	Formulations de comprimes de valsartan
TR200703568A1 (tr)	2007-05-24	2008-07-21	Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket�	Valsartan formülasyonları
AU2008311053B2 (en)	2007-10-09	2012-08-30	Novartis Ag	Pharmaceutical formulation of valsartan
SI2217205T1 (sl)	2007-11-06	2015-10-30	Novartis Ag	Farmacevtske sestave na podlagi superstruktur zaviralca/blokatorja angiotenzinskih receptorjev (arb) in inhibitorja nevtralne endopeptidaze (nep)
WO2009092052A2 (fr) *	2008-01-18	2009-07-23	Massachusetts Eye And Ear Infirmary	Procédés et compositions pour traiter des polypes
GB0802931D0 (en) *	2008-02-18	2008-03-26	Queen Mary & Westfield College	Synthetic scFv analogue to the 6313/G2 (anti angiotensin II type 1 receptor) monoclonal anitbody variable regions
WO2010104485A2 (fr)	2009-03-11	2010-09-16	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	Préparations de valsartan
WO2011102702A2 (fr)	2010-02-16	2011-08-25	Krka, D. D., Novo Mesto	Procédé pour la préparation de formes posologiques solides orales comprenant du valsartan
EP2455388A1 (fr)	2010-11-23	2012-05-23	LanthioPep B.V.	Nouveaux agonistes du récepteur 2 (AT2) de type angiotensine et leurs utilisations
CN102266307B (zh) *	2011-08-01	2012-10-24	海南锦瑞制药股份有限公司	一种缬沙坦胶囊及其制备方法
WO2013098576A1 (fr)	2011-12-31	2013-07-04	Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi	Composition pharmaceutique de valsartan à libération immédiate
WO2013098578A1 (fr)	2011-12-31	2013-07-04	Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi	Composition pharmaceutique d'hydrochlorothiazide de valsartan à libération immédiate
EA018867B1 (ru) *	2012-11-01	2013-11-29	Лаборатория Тютор С.А.С.И.Ф.И.А.	Способ получения фармацевтической композиции и продукт способа
EP4007592A1 (fr)	2019-08-02	2022-06-08	LanthioPep B.V.	Agonistes du récepteur de l'angiotensine 2 (at2) destinés à être utilisés dans le traitement du cancer
EP4295839A1 (fr)	2022-06-20	2023-12-27	KRKA, d.d., Novo mesto	Combinaison de valsartan et d'indapamide
WO2024026528A1 (fr) *	2022-08-02	2024-02-08	Dimerix Bioscience Pty Ltd	Régime posologique pour le traitement de la bpco

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3146168A (en) *	1962-04-10	1964-08-25	Fmc Corp	Manufacture of pharmaceutical preparations containing cellulose crystallite aggregates
CA1334092C (fr)	1986-07-11	1995-01-24	David John Carini	Imidazoles bloquant les recepteurs de l'angiotensine ii
ES2060737T3 (es) *	1988-02-25	1994-12-01	Yamanouchi Europ Bv	Procedimiento de preparacion de un granulado farmaceutico.
ATE190051T1 (de)	1989-06-14	2000-03-15	Smithkline Beecham Corp	Imidazoalkensäure
IE70593B1 (en)	1989-09-29	1996-12-11	Eisai Co Ltd	Biphenylmethane derivative the use of it and pharmacological compositions containing same
ES2084801T3 (es)	1990-02-19	1996-05-16	Ciba Geigy Ag	Acil compuestos.
IE910913A1 (en)	1990-03-20	1991-09-25	Sanofi Sa	N-substituted heterocyclic derivates, their preparation¹and pharmaceutical compositions containing them
US5196444A (en)	1990-04-27	1993-03-23	Takeda Chemical Industries, Ltd.	1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
IL99246A0 (en)	1990-09-10	1992-07-15	Abbott Lab	Angiotensin ii receptor antagonists and pharmaceutical compositions containing them
JP3208139B2 (ja) *	1990-10-02	2001-09-10	ワーナー−ランバート・コンパニー	アンギオテンシン▲ｉｉ▼アンタゴニスト
DE4038335A1 (de) *	1990-12-01	1992-06-04	Boehringer Mannheim Gmbh	Neue pyridinderivate, verfahren zu ihrer herstellung und verwendung als arzneimittel
SI9210098B (sl) *	1991-02-06	2000-06-30	Dr. Karl Thomae	Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
US5614519A (en) *	1991-02-06	1997-03-25	Karl Thomae Gmbh	(1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists
US5196537A (en)	1991-03-21	1993-03-23	G. D. Searle & Co.	5-apylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
GB9110636D0 (en)	1991-05-16	1991-07-03	Glaxo Group Ltd	Chemical compounds
DE4132632A1 (de) *	1991-10-01	1993-04-08	Bayer Ag	Substituierte imidazolyl-propensaeurederivate
DE4309968A1 (de) *	1993-03-26	1994-09-29	Bayer Ag	Phenylglycinamide von heterocyclisch substituierten Phenylessigsäurederivaten
DK0636027T3 (da)	1992-04-13	2000-01-31	Zeneca Ltd	Angiotensin-II-antogonister mod sygdomme forbundet med forringet neuronal ledningshastighed, især diabetisk neuropati
WO1994013642A1 (fr) *	1992-12-11	1994-06-23	Ciba-Geigy Ag	Benzazepinones substituees
WO1994013651A1 (fr)	1992-12-11	1994-06-23	Ciba-Geigy Ag	Derives de benzazepinone
DE4309963A1 (de) *	1993-03-26	1994-09-29	Hubert Kamperschroer	Faß zum Austragen von Gülle
FR2716882B1 (fr) *	1994-03-04	1996-04-05	Roussel Uclaf	Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques.
DE4408497A1 (de) *	1994-03-14	1995-09-21	Thomae Gmbh Dr K	Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO1995024901A1 (fr) *	1994-03-17	1995-09-21	Ciba-Geigy Ag	Traitement de la nephropathie diabetique a l'aide de valsartan
DE4432860A1 (de) *	1994-09-15	1996-03-21	Merck Patent Gmbh	Imidazopyridine
JPH11513395A (ja)	1995-10-06	1999-11-16	ノバルティス・アクチエンゲゼルシャフト	虚血後腎不全の予防および処置並びに虚血腎臓の保護のためのａｔ１−レセプターアンタゴニスト
WO1997031624A1 (fr)	1996-02-27	1997-09-04	Purdue Research Foundation	Systeme d'apport de liposome
US6174910B1 (en) *	1996-02-29	2001-01-16	Novartis Ag	AT1 receptor antagonist for the stimulation of apoptosis
GB9613470D0 (en) *	1996-06-27	1996-08-28	Ciba Geigy Ag	Small solid oral dosage form
DE19628617A1 (de) *	1996-07-16	1998-01-22	Basf Ag	Direkttablettierhilfsmittel
EP2322174B1 (fr)	1998-07-10	2015-09-23	Novartis Pharma AG	Utilisation combinée de valsartane et bloqueurs du canal de calcium à but thérapeutique
CZ20012682A3 (cs)	1999-01-26	2001-10-17	Novartis Ag	Pouľití antagonistů receptoru angiotensinu II pro léčení akutního infarktu myokardu
KR100525341B1 (ko) *	2000-06-22	2005-11-02	노파르티스 아게	고형 발사르탄 약제학적 조성물
US20070123498A1 (en)	2003-10-17	2007-05-31	Shetty Suraj S	Combination of organic compounds
JP2009018990A (ja)	2005-10-25	2009-01-29	Univ Kurume	Ｃ型肝炎ウイルス由来ペプチド

1999
- 1999-12-22 KR KR1020017007996A patent/KR100646716B1/ko not_active IP Right Cessation
- 1999-12-22 DK DK99964665T patent/DK1140071T3/da active
- 1999-12-22 ID IDW00200101299Q patent/ID29856A/id unknown
- 1999-12-22 TR TR2002/00764T patent/TR200200764T2/xx unknown
- 1999-12-22 NZ NZ587909A patent/NZ587909A/en not_active IP Right Cessation
- 1999-12-22 PT PT05013209T patent/PT1588706E/pt unknown
- 1999-12-22 EP EP05013209A patent/EP1588706B1/fr not_active Revoked
- 1999-12-22 TR TR2008/05740T patent/TR200805740T1/xx unknown
- 1999-12-22 NZ NZ511938A patent/NZ511938A/xx not_active IP Right Cessation
- 1999-12-22 AU AU30430/00A patent/AU3043000A/en not_active Abandoned
- 1999-12-22 TR TR2001/01784T patent/TR200101784T2/xx unknown
- 1999-12-22 CN CNB998150452A patent/CN1304000C/zh not_active Expired - Fee Related
- 1999-12-22 AT AT05013209T patent/ATE524176T1/de active
- 1999-12-22 WO PCT/EP1999/010330 patent/WO2000038676A1/fr active IP Right Grant
- 1999-12-22 EP EP99964665A patent/EP1140071B1/fr not_active Revoked
- 1999-12-22 TR TR2008/05275T patent/TR200805275T2/xx unknown
- 1999-12-22 IL IL14323399A patent/IL143233A0/xx not_active IP Right Cessation
- 1999-12-22 TR TR2008/05741T patent/TR200805741T2/xx unknown
- 1999-12-22 CA CA2622805A patent/CA2622805C/fr not_active Expired - Fee Related
- 1999-12-22 AT AT99964665T patent/ATE354364T1/de not_active IP Right Cessation
- 1999-12-22 CN CNA200410087973XA patent/CN1636561A/zh active Pending
- 1999-12-22 ES ES99964665T patent/ES2281978T3/es not_active Expired - Lifetime
- 1999-12-22 JP JP2000590630A patent/JP2002533390A/ja not_active Withdrawn
- 1999-12-22 PL PL349424A patent/PL199100B1/pl not_active IP Right Cessation
- 1999-12-22 NZ NZ553010A patent/NZ553010A/en not_active IP Right Cessation
- 1999-12-22 EP EP10010334A patent/EP2298298A3/fr not_active Withdrawn
- 1999-12-22 RU RU2001119990/15A patent/RU2271809C2/ru not_active IP Right Cessation
- 1999-12-22 CZ CZ20032559A patent/CZ297795B6/cs not_active IP Right Cessation
- 1999-12-22 DK DK05013209.1T patent/DK1588706T3/da active
- 1999-12-22 SI SI9930963T patent/SI1140071T1/sl unknown
- 1999-12-22 CZ CZ20012306A patent/CZ293257B6/cs not_active IP Right Cessation
- 1999-12-22 ES ES05013209T patent/ES2373556T3/es not_active Expired - Lifetime
- 1999-12-22 HU HU0104780A patent/HUP0104780A3/hu unknown
- 1999-12-22 SK SK913-2001A patent/SK9132001A3/sk unknown
- 1999-12-22 TR TR2006/05471T patent/TR200605471T2/xx unknown
- 1999-12-22 CA CA002351357A patent/CA2351357A1/fr not_active Abandoned
- 1999-12-22 TR TR2006/05472T patent/TR200605472T1/xx unknown
- 1999-12-22 BR BR9916576-7A patent/BR9916576A/pt not_active IP Right Cessation
- 1999-12-22 PT PT99964665T patent/PT1140071E/pt unknown
- 1999-12-22 DE DE69935249T patent/DE69935249T2/de not_active Revoked
- 1999-12-22 SI SI9931064T patent/SI1588706T1/sl unknown
2001
- 2001-05-17 IL IL143233A patent/IL143233A/en not_active IP Right Cessation
- 2001-06-22 NO NO20013143A patent/NO328775B1/no not_active IP Right Cessation
2002
- 2002-01-28 HK HK02100661.6A patent/HK1038888B/zh not_active IP Right Cessation
2003
- 2003-12-02 AU AU2003266433A patent/AU2003266433B2/en not_active Ceased
2005
- 2005-08-01 RU RU2005124363/15A patent/RU2361575C2/ru not_active IP Right Cessation
2006
- 2006-07-18 AU AU2006203077A patent/AU2006203077B2/en not_active Expired
- 2006-11-02 IL IL179017A patent/IL179017A0/en unknown
- 2006-11-02 IL IL179016A patent/IL179016A0/en unknown
- 2006-11-02 IL IL179015A patent/IL179015A0/en unknown
2007
- 2007-05-10 CY CY20071100642T patent/CY1106581T1/el unknown
2008
- 2008-11-05 RU RU2008143545/15A patent/RU2008143545A/ru unknown
2009
- 2009-09-24 AU AU2009220022A patent/AU2009220022B2/en not_active Expired
2010
- 2010-01-12 NO NO20100041A patent/NO20100041L/no not_active Application Discontinuation
- 2010-01-18 JP JP2010008140A patent/JP5254258B2/ja not_active Expired - Lifetime
2011
- 2011-12-06 CY CY20111101213T patent/CY1112395T1/el unknown

Also Published As

Publication number	Publication date
ATE354364T1 (de)	2007-03-15
DE69935249T2 (de)	2007-10-31
CA2622805C (fr)	2011-05-10
NO20013143L (no)	2001-08-16
CN1331590A (zh)	2002-01-16
CA2622805A1 (fr)	2000-07-06
NO20100041L (no)	2001-08-16
IL179015A0 (en)	2007-03-08
TR200805741T2 (tr)	2008-10-21
NZ587909A (en)	2012-05-25
CZ293257B6 (cs)	2004-03-17
AU2003266433B2 (en)	2006-08-10
TR200805740T1 (tr)	2010-06-21
TR200605472T1 (tr)	2007-02-21
PT1140071E (pt)	2007-05-31
CZ20012306A3 (cs)	2001-12-12
HK1038888B (zh)	2007-09-21
ES2281978T3 (es)	2007-10-01
JP2010090169A (ja)	2010-04-22
EP1588706A2 (fr)	2005-10-26
AU2006203077A1 (en)	2006-08-10
EP1140071A1 (fr)	2001-10-10
JP2002533390A (ja)	2002-10-08
NZ511938A (en)	2004-02-27
IL143233A (en)	2007-07-24
EP2298298A3 (fr)	2011-05-11
IL143233A0 (en)	2002-04-21
AU2006203077B2 (en)	2009-10-08
JP5254258B2 (ja)	2013-08-07
TR200200764T2 (tr)	2002-07-22
CN1304000C (zh)	2007-03-14
EP1588706A3 (fr)	2005-12-07
TR200605471T2 (tr)	2006-11-21
KR20010089681A (ko)	2001-10-08
DK1588706T3 (da)	2012-01-16
AU3043000A (en)	2000-07-31
RU2005124363A (ru)	2007-02-10
HUP0104780A3 (en)	2002-11-28
RU2361575C2 (ru)	2009-07-20
NO328775B1 (no)	2010-05-10
RU2008143545A (ru)	2010-05-10
TR200805275T2 (tr)	2008-09-22
EP1588706B1 (fr)	2011-09-14
AU2009220022A1 (en)	2009-10-15
SI1588706T1 (sl)	2012-01-31
HUP0104780A2 (hu)	2002-04-29
EP2298298A2 (fr)	2011-03-23
CY1106581T1 (el)	2012-01-25
EP1140071B1 (fr)	2007-02-21
DE69935249D1 (de)	2007-04-05
SI1140071T1 (sl)	2007-08-31
RU2271809C2 (ru)	2006-03-20
CZ297795B6 (cs)	2007-03-28
NZ553010A (en)	2008-09-26
ATE524176T1 (de)	2011-09-15
AU2003266433A1 (en)	2004-01-08
BR9916576A (pt)	2001-10-02
CA2351357A1 (fr)	2000-07-06
NO20013143D0 (no)	2001-06-22
ID29856A (id)	2001-10-18
CN1636561A (zh)	2005-07-13
TR200101784T2 (tr)	2001-10-22
IL179016A0 (en)	2007-03-08
PL199100B1 (pl)	2008-08-29
PL349424A1 (en)	2002-07-29
PT1588706E (pt)	2011-12-21
CY1112395T1 (el)	2015-12-09
AU2009220022B2 (en)	2011-11-03
ES2373556T3 (es)	2012-02-06
DK1140071T3 (da)	2007-06-04
WO2000038676A1 (fr)	2000-07-06
HK1038888A1 (en)	2002-04-04
KR100646716B1 (ko)	2006-11-17
IL179017A0 (en)	2007-03-08

Legal Events

Date	Code	Title	Description
2015-05-05	FB9A	Suspension of patent application procedure

Publication	Publication Date	Title
SK9132001A3 (en)	2002-01-07	Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
US20100120877A1 (en)	2010-05-13	Additional therapeutic use
JP2003519681A (ja)	2003-06-24	グルブリド組成物
JP6860949B2 (ja)	2021-04-21	癌の処置方法
TW202120086A (zh)	2021-06-01	治療癌症之方法
EP1013273A1 (fr)	2000-06-28	Utilisation des antagonistes du recepteur AT-1 ou des modulateurs du recepteur AT-2 pour le traitement de maladies asocciées à une augmentation de recepteurs AT-1 ou AT-2
WO2023125724A1 (fr)	2023-07-06	Composition pharmaceutique solide
KR20080031005A (ko)	2008-04-07	미분화되지 않은（4-클로로페닐）［4-（4-피리딜메틸）프탈라진-1-일］ 및이의 염의 즉각-방출형 고-약물-로드 제약 제제
TW202206074A (zh)	2022-02-16	藥物配製物